Media stories about Check-Cap (NASDAQ:CHEK) have trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Check-Cap earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 45.4248913935649 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

A number of analysts recently issued reports on CHEK shares. Zacks Investment Research upgraded shares of Check-Cap from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a research report on Wednesday, May 24th. ValuEngine upgraded shares of Check-Cap from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Finally, Maxim Group restated a “buy” rating on shares of Check-Cap in a research report on Tuesday, May 30th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $5.00.

Shares of Check-Cap (CHEK) opened at 1.8499 on Wednesday. The company’s 50-day moving average is $1.86 and its 200-day moving average is $2.08. The firm’s market cap is $28.91 million. Check-Cap has a 12 month low of $1.72 and a 12 month high of $2.95.

ILLEGAL ACTIVITY WARNING: “Check-Cap (NASDAQ:CHEK) Getting Somewhat Positive News Coverage, Study Finds” was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/09/check-cap-nasdaqchek-getting-somewhat-positive-news-coverage-study-finds.html.

Check-Cap Company Profile

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Insider Buying and Selling by Quarter for Check-Cap (NASDAQ:CHEK)

Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.